Limitations of the MTT assay in cell viability testing

Advances in Clinical and Experimental Medicine

Volumn 17, Issue 5, 2008, Pages 525-529

  Jaszczyszyn, Agata ^a   Gasiorowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Doxorubicin; Fluphenazine; Lymphocyte cultures; MTT assay; PI exclusion test

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; FLUPHENAZINE; PROPIDIUM IODIDE;

ARTICLE; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL DEATH; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY TEST; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; LYMPHOCYTE CULTURE; MTT ASSAY; RELIABILITY; SPECTROPHOTOMETER; SPECTROPHOTOMETRY; VALIDITY;

EID: 57649230168     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolinum dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 83, 271-277.
2. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65, 55-63.
3. Collier AC, Pritsos ChA: The mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem Pharmacol 2003, 66, 281-287.
4. Gonzalez RJ, Tarloff JB: Evaluation of hepatic subcellular fraction for alamar blue and MTT reductase activity. Toxicol in Vitro 2001, 15, 257-259.
5. Belyanskaya L, Manser P, Spohn P, Bruinink A, Wick P: The reliability and limits of the MTT reduction assay for carbon nanotubes-cell interaction. Carbon 2007, 45, 2643-2648.
6. Gasiorowski K, Brokos B, Szyba K, Leszek J: Antimutagenic activity of fluphenazine in short-term tests. Mutagenesis 2001, 16, 31-38.
7. Gasiorowski K, Malinka W, Światek P, Jaszczyszyn A: Antimutagenic activity of new analogues of fluphenazine. Cell Mol Biol Lett 2003, 8, 927-942.
8. Dengler WA, Schulte J, Berger AP, Mertelsmann R, Fiebig HH: Development of a propidium iodide assay for proliferation and cytotoxicity assays. Anti-Cancer Drug 1995, 6, 1-16.
9. Hofman FM, Kanesberg B, Smith D: Stability of T- and B-cell numbers in human peripheral blood. Amer J Clin Pathol 1982, 77, 710-712.
10. McDevitt ChA, Callaghan R: How can we best use structural information on P-glycoprotein to design inhibitors? Pharm Therap 2007, 113, 429-441.
11. Liu Y, Petersen DA, Kimura H, Schubert D: Mechanism of cellular 3-(4,5- dimethylthiazol-2-yl)-2,5-dipphenyltetrazolium bromide (MTT) reduction. J Neurochem 1997, 69, 581-593.
12. Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M: The MTT assay yields a relatively lower results of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol in Vitro 2008, 22, 232-239.
13. Chakrabarti R, Kundu S, Kumar S, Chakrabarti R: Vitamin A as an enzyme that catalyzes the reduction of MTT to formazan by vitamin C. J Cell Biochem 2000, 18, 133-138.
14. Peng L, Wang B, Ren P: Reduction of MTT by flavonoids in the absence of cells. Colloids Surf B, Biointerfaces 2005, 45, 108-111.
15. Weyermann J, Lochmann D, Zimmer A: A practical note on the use of cytotoxicity assays. Int J Pharm 2005, 288, 369-376.
16. Bruggisser R, von Daeniken K, Jundt G, Schaffner W, Tuliberg-Reinert H: Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med 2002, 68, 445-448.
17. Vellonen KS, Honkakoski P, Urtti A: Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur J Parm Sci 2004, 181-188.
18. Jaszczyszyn A, Gasiorowski K: Mechanizmy chemoprewencyjnego działania nowo syntezowanych analogów flufenazyny. Borgis Wydawnictwo Medyczne, Warszawa 2006, 94-149.